Andrew Douglas Baxter

This inventor holds 44 USPTO granted patents and 2 published patent applications, plus 2 CIPO patents and 2 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Darwin Discovery Limited, Chiroscience, Ltd., Pfizer Corporation. Active years: 1997-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Douglas Baxter. Retrieved from https://idiyas.com/inventor/andrew-douglas-baxter

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 44 (Patent Applications = 2)

% Patents Active = 56.8

CIPO Patents = 2 (Patent Applications = 23)

EPO Patents = 2

Average Co-Inventor Count = 3.6

ph-index = 9

Forward Citations = 264(Granted Patents)

Location History:

Essex, GB (2010)
Sandwich, GB (2006 - 2011)
Cambridge, GB (1997 - 2014)

Company Filing History:

30 out of 90

Darwin Discovery Limited

Years Active: 1997-2014

Loading Chart...

Areas of Expertise:

Glycopyrronium Bromide

Beta-Aminoalcohols

Bupropion Metabolites

Morpholine Agonists

Triazole Compounds

Hydroxamic Acid Derivatives

Selective MMP Inhibitors

Peptidyl Compounds

Carboxylic Acid Derivatives

Therapeutic Use

Inflammatory Disorders

Quinolones

44 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8846954 - Crystallisation and purification of glycopyrronium bromide (2014-09-30),

2. 8188150 - Use of beta-aminoalcohols in the treatment of inflammatory disorders and pain (2012-05-29),

3. 8030357 - Use of bupropion metabolites for the treatment of inflammatory disorders (2011-10-04),

4. 7915303 - Glycopyrronium salts and their therapeutic use (2011-03-29),

5. 7902188 - Morpholine dopamine agonists (2011-03-08),

6. 7728035 - Ester derivatives of rhein and their therapeutic use (2010-06-01),

7. 7576081 - Morpholine dopamine agonists (2009-08-18),

8. 7323462 - Morpholine dopamine agonists (2008-01-29),

9. 7084145 - Triazole compounds useful in therapy (2006-08-01),

10. 6933306 - Hydroxamic and carboxylic acid derivatives (2005-08-23),

11. 6818622 - Selective MMP inhibitors having reduced side-effects (2004-11-16),

12. 6809100 - Hydroxamic acid derivatives (2004-10-26),

13. 6787536 - Hydroxamic acid derivatives (2004-09-07),

14. 6734189 - Hydroxamic and carboxylic acid derivatives (2004-05-11),

15. 6706719 - Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity (2004-03-16),

Title: The Inventor Spotlight: Andrew Douglas Baxter

Introduction: Andrew Douglas Baxter, a prolific inventor based in Cambridge, GB, is renowned for his remarkable contributions in the field of pharmaceutical innovations. With an impressive portfolio of 40 patents to his name, Baxter has solidified his position as a leading figure in the industry.

Latest Patents: Among his recent patents is the groundbreaking method for the crystallisation and purification of glycopyrronium bromide. This innovative technique involves the precise reaction of glycopyrronium base with methyl bromide in a carefully selected solvent, resulting in the desired diastereoisomers with remarkable particle size distribution. Additionally, Baxter has introduced the use of beta-aminoalcohols in the treatment of inflammatory disorders and pain, providing a novel therapeutic compound to address these medical conditions.

Career Highlights: Baxter has held key roles at prestigious companies such as Darwin Discovery Limited and Chiroscience Ltd., where his expertise and ingenuity have driven significant advancements in pharmaceutical research and development. His relentless pursuit of innovation and commitment to excellence have set him apart as a pioneer in the field.

Collaborations: Throughout his illustrious career, Baxter has collaborated with esteemed professionals in the industry, including notable coworkers John Gary Montana and David Alan Owen. Together, they have spearheaded numerous projects and initiatives that have reshaped the landscape of pharmaceutical innovation.

Conclusion: In conclusion, Andrew Douglas Baxter's innovative spirit, combined with his exceptional talent and dedication, has propelled him to the forefront of the pharmaceutical industry. His groundbreaking patents and collaborative efforts underscore his significant contributions to the field, making him a true visionary in the world of inventions and innovations.

Profile summary based on public USPTO records.